

CORRELATION OF PLASMINOGEN ACTIVATOR INHIBITOR AND ANGIOTENSIN-CONVERTING ENZYME GENES WITH MISSED MISCARRIAGE IN THE FIRST HALF OF PREGNANCY

* Eman Abdulazeez Hussein

MBCHB, Duhok hospital of obstetric and gynecology, Kurdistan Region-Iraq e-mail:
emanabdullazizhusseintahamziri@gmail.com

**Iman Yousif Abdulmalik

Department of obstetrics and gynecology, college of medicine, university of Duhok, kurdistan
Region-Iraq e-mail: eman.malik@uod.ac

Abstract

Background: Recurrent miscarriage stands as a significant public health issue, affecting 2%-5% of women in their childbearing years. It is characterized by the occurrence of three or more consecutive pregnancy losses before reaching viability, encompassing all miscarriages from conception to the 20th week of gestation. Thrombotic disorders are identifiable in 40–50% . Our Aim is To study the relation of the common polymorphisms in Angiotensin converting enzyme and plasminogen activator inhibitor-1 with recurrent miscarriage.

Patients and Methods: This comparative observational prospective case-control study was carried out at Duhok Hospital for Obstetrics and Gynecology during the period from January 1st to September 1st, 2023, it included 100 married women in age range (18-42 years), as 50 women with a history of three or more miscarriages during the first half of pregnancy and fifty women as controls with a history of at least one successful pregnancy. Data were collected through a questionnaire form and blood tests targeting these thrombophilia genes (Angiotensin converting enzyme and plasminogen activator inhibitor-1).

Results: This study showed that women with history of Recurrent miscarriage had a significant association with plasminogen activator inhibitor I with ($P= 0.009$), but no association with angiotensin-converting enzyme genes, the ($P= 0.275$). In addition, the recurrent miscarriage has a significant association with parity ($P \leq 0.001$), while did not associated with each BMI and supplement taking.

Conclusions: The genetic marker PAI-1 is playing a discernible role in recurrent miscarriage while ACE gene does not show any significant impact.

Keywords: Angiotensin-converting enzyme, Plasminogen activator inhibitor-1, recurrent miscarriage.

INTRODUCTION

1.1 Background:

Recurrent miscarriage is one of the top public health concerns, accounting for 2- 5% of women of childbearing age ¹. Recurrent miscarriage is defined as the loss of three or more consecutive pregnancies before viability and includes all pregnancy losses from the time of conception through 20 weeks gestation ²⁻⁴. The most commonly reported causes of miscarriage are structural chromosomal abnormalities in one of the partners, uterine abnormalities, randomly elevated homocysteine levels, and antiphospholipid syndrome ^{5,6}.

Thrombophilia is described as a susceptibility to arterial or venous thrombotic complications due to defects in the hemostatic system, which may be acquired, such as antiphospholipid syndrome, or inherited ^{7,8}. Adverse pregnancy outcomes such as pregnancy failures (i.e, sporadic and recurrent miscarriage, later fetal loss), preeclampsia, and HELLP syndrome are associated with thrombotic mechanisms and thrombophilia ⁹. Thrombotic disorders are detectable in 40–50% of recurrent

miscarriage cases¹⁰⁻¹².

Clinically recognized miscarriage occurs in approximately 15-25% of all pregnancies. It is estimated that less than 5% of women experience two consecutive miscarriage and that only 1% of women experience three or more miscarriage¹³.

Possible causes of recurrent miscarriage could be anatomical, immunological, genetics, endocrine, environmental and thrombophilic factors. It is known that the ACE gene contains a polymorphism consisting of either the insertion (I) or the deletion (D) of a 287 bp Alu repetitive sequence in intron¹⁴. In particular, the D allele and DD genotype are associated with elevated ACE levels¹⁵⁻¹⁷. Homozygotes for the I allele may have only half the plasma ACE level compared to homozygotes for the D allele, whereas the ID heterozygotes have an intermediate value¹⁸. The uteroplacental RAS assumes a crucial role in the regeneration of the endometrium post-shedding, decidualization, implantation, and placentation. Furthermore, the local RAS actively contributes to prostaglandin production, the release of estradiol, and the control of blood flow to the placenta and uterus¹⁹.

PAI-1, a single-chain glycoprotein, member of the serine protease inhibitor superfamily, is one of the most important inhibitors of fibrinolytic activity in plasma. PAI-1 is the major inhibitor of tissue-type plasminogen activator (t-PA) and urine-type plasminogen activator (u-PA). The increased expression of PAI-1 in vivo suppresses fibrinolysis, consequently leading to pathological fibrin deposition and tissue damage. A number of previous studies have examined the association of the polymorphisms PAI-1 4G/5G and ACE I/D with infertility, Recurrent miscarriage and serious pregnancy complications²⁰.

In the review of literature of the surrounding area like Iran and Sudan, Considering all their results, the pooled data indicated that ACE I/D and PAI-1 4G/5G polymorphisms were associated with an increased risk of recurrent miscarriage. Moreover, these polymorphisms were associated with recurrent miscarriage risk by the number of previous miscarriages. These significant findings suggest that investigation might be adequate for ACE I/D and PAI-1 4G/5G polymorphisms in association with recurrent miscarriage and should be part of the standard examination for all women with recurrent miscarriage²¹.

According to the Knowledge there is no study about the association between the ACE I/D and PAI-1 4G/5G polymorphisms and recurrent miscarriage in Duhok, so this study was done to investigate them. Patients and Methods: A comparative prospective observational case-control study design was adopted. The research took place at Duhok Hospital for Obstetrics and Gynecology, spanning from January 1st to September 1st, 2023. The Ethical Committee of the Duhok Directorate of Health and the Scientific Committee of Duhok Hospital of Obstetrics & Gynecology formally endorsed the study proposal. Each woman invited to participate was verbally briefed about the study, with the assurance that the data would be used exclusively for the study's purposes.

Data Collection Tool and analysis :

Patient responses to the checklist questionnaire during interviews and file reviews by the researcher constituted the data collection. The questionnaire form (see Appendix B) included information about age, residence, educational levels, occupations, and economic status. Gravidity, parity, and the number of recurrent miscarriage were assessed. Past medical history (PMH), past surgical history (PSH), family, social, and psychological history were considered. The weight, height, and body mass index (BMI) were measured during the examination. The types of supplements were also evaluated.

Blood samples were collected and sent to the laboratory for DNA extraction and genotype analysis by Roter gene (CVD), to investigate the association between ACE insertion and deletion I/D (homozygous or heterozygous) and plasminogen activator inhibitor insertion and deletion 4G/5G (homozygous or heterozygous) in women experiencing missed miscarriage. And The statistical analysis that used in present study were frequency, percentage, mean, and standard deviation as descriptive

analysis and Chi square and Fisher exact test as inferential analysis with P value of <0.05 considered as statistically significant.

RESULTS

3.1. The Socio- demographic Characteristics of the Study Sample.

Table 3.1 shows that most of the pregnant women aged between 25-30 have no recurrent miscarriage, while 37-42 stand for Recurrent miscarriage 20(40%), 15(30%) respectively, in both the large proportion, are residents of urban areas 50(100%), 36(72%) and secondary school graduate 29(58%), 23(46%), and have enough monthly household income 46(92%), 32(64%) as presented respectively, however (48%) of control are governmental employee and (52%) of those with recurrent miscarriage are housewife worked. Besides, recurrent miscarriage is associated with each pregnant woman's age, residence, occupation, and economic status with P-values 0.036, ≤ 0.001, 0.002, and 0.003 respectively.

Table 3.1: Pregnant Women Demographic Characteristics and their Association with Recurrent Pregnancy Loss.

		Miscarriage		P- Value
		Control F (%)	Recurrent miscarriage 3 and more F (%)	
Age	19-24	10 (20)	9 (18)	0.036*
	25-30	20 (40)	12 (24)	
	31-36	16 (32)	14 (28)	
	37-42	4 (8)	15 (30)	
Age Mean (SD)		30.74 (6.159)		
Residence	Urban	50 (100)	36 (72)	≤ 0.001*
	Rural	0 (0)	14 (28)	
Educational level	Primary school	8 (16)	12(24)	0.342**
	Secondary school	29 (58)	23 (46)	
	Tertiary & above	13 (26)	15 (30)	
Occupation: Employment status	Housewife worked	10 (20)	26 (52)	0.002*
	Government employee	24 (48)	18 (36)	
	Non-governmental employee	16 (32)	6 (12)	
Economic status (Monthly household income)	Not enough	1 (2)	5 (10)	0.003**
	Enough	46 (92)	32 (64)	
	Enough and more	3 (6)	13 (26)	

* Chi square ** Fisher exact test

3.2. The Obstetrical Characteristics of the Study Sample.

Table 3.2 reveals that most of the pregnant women who had recurrent miscarriage did not do the investigation of the previous recurrent miscarriage 37(74%) and were normal previous U/S 46(92%), and a large proportion of both groups are overweight 26(52%), multi para 26 (52%), 21 (42%), and taking folic acid 48(96%), 50(100%), respectively. In addition, abortion has a significant association

with parity P -Value ≤ 0.001 , while did no association with each BMI and supplement taking.

Table 3.2: Pregnant women's Obstetrical Characteristics and their association with recurrent pregnancy loss.

		miscarriage		P - Value
		Control F (%)	Recurrent miscarriage 3 and more F (%)	
Investigation of the previous recurrent miscarriage	Yes No	0 (0) 50 (100)	13 (26) 37 (74)	
Previous U/S	Normal Presence of deformity	50 (100) 0 (0)	46 (92) 4 (8)	
BMI	Underweight (BMI below 18.5) Healthy weight (BMI 18.5 to 24.9) Overweight (BMI 25 to 29.9) Obese (BMI 30 or more)	0 (0) 10 (20) 26 (52) 14 (28)	1 (2) 7 (14) 22 (44) 20 (40)	0.381**
Parity	Para (0) Primi para Multi para (2-4) Grand multi para (\Rightarrow 5)	0 (0) 24 (48) 26 (52) 0 (0)	14 (28) 14 (28) 21 (42) 1 (2)	≤ 0.001 **
Supplement Taking	Folic acid Vitamin D Multivitamin	48 (96) 12 (24) 17 (34)	50 (100) 12 (24) 16 (32)	0.968*

* Chi square ** Fisher exact test

3.3 Women's Past History Variables of Study Sample.

This table presents that most of the pregnant women in both groups had no either chronic disease 43 (86%), 39 (78%), surgical history 27 (54%), 17 (34%), family history of thrombophilia 47 (94%), 49 (98%), Social behavior history 40 (80), 41 (82), and stress 43 (86), 41 (82). At the same time, recurrent miscarriage has a highly significant association with the pregnant women past surgical history P -Value ≤ 0.001 while no association with rest.

Table 3.3: Pregnant Women’s Past History Variables and their Association with Recurrent Pregnancy Loss

		miscarriage		P- Value
		Control F (%)	Recurrent miscarriage 3 and more F (%)	
Past medical history	HTN	4 (8)	3 (6)	0.389**
	DM	3 (6)	7 (14)	
	Autoimmune disease	0 (0)	1 (2)	
	No Chronic diseases	43 (86)	39 (78)	
Past surgical history	No Surgical History	27 (54)	17 (34)	≤ 0.001**
	CS	22 (44)	12 (24)	
	D&C	0 (0)	25 (50)	
	Laparoscope	1 (2)	9 (18)	
	Previous operation	0 (0)	1 (2)	
	Hysteroscope	1 (2)	3 (6)	
Family history	Thrombophilia	3 (6)	1 (2)	0.617**
	None	47 (94)	49 (98)	
Social behavior history	Hadn't Smoking	40 (80)	41 (82)	0.399**
	Alcohol	8 (16)	7 (14)	
	Caffeine	2 (4)	0 (0)	
		0 (0)	2 (4)	
Psychological history	Stress	7 (14)	8 (16)	0.786**
	No stress	43 (86)	41 (82)	
	Under treatment	0 (0)	1 (2)	

* Chi square ** Fisher exact test

3.4. The Association of Miscarriage with each (PAI-1) and (ACE) Genes in the Study Sample.

Table 3.4 displays that the history of recurrent miscarriage has a highly significant association with Plasminogen activator inhibitor 1, but no association with Angiotensin-Converting Enzyme genes.

Table (3.4): The Association of Miscarriage with each of Plasminogen Activator Inhibitor 1 (PAI-1) 4G/5G and Angiotensin- Converting Enzyme genes (ACE) 287bp insertion/deletion (I/D).

Thrombophilic Genes (ACE, PAI-1)		Miscarriage		P- Value
		Control F (%)	Recurrent miscarriage 3 and more F (%)	
Plasminogen activator inhibitor 1 (PAI-1) 4G/5G	Normal	6 (12)	8 (16)	0.009*
	Homozygote	33 (66)	18 (36)	
	Heterozygote	11 (22)	24 (48)	

Angiotensin- Enzyme genes (ACE) insertion/deletion (I/D)	Converting 287 bp Homozygote	Normal 8 (16)	3 (6)	0.275*
		24 (48)	26 (52)	
	Heterozygote	18 (36)	21 (42)	

* Chi-square

Discussion

Successful embryo implantation depends on regulating coagulation and fibrinolysis to prevent excessive fibrin accumulation in placental vessels and intervillous spaces. Research into ACE I/D and PAI-1 polymorphisms has explored their potential links to recurrent miscarriage. The ACE I/D polymorphism, associated with conditions like stroke and preeclampsia, impacts miscarriage risk by influencing thrombotic events. The D allele is linked to higher ACE levels, increasing thrombotic risk^{21, 22, 23}.

Elevated PAI-1 levels, influenced by the ACE I/D polymorphism, also correlate with miscarriage risk^{24, 25}. Despite numerous studies, results have been inconsistent.

This study found a significant association between recurrent miscarriage and PAI-1 but not ACE genes, aligning with Aarabi et al.²⁶, who found the 4G/4G genotype of PAI-1 significantly linked to higher miscarriage risk. This contrasts with Fazelnia et al.²³, who reported a significant association between the DD genotype of the ACE I/D polymorphism and recurrent miscarriage in northern Iran. Similar results were noted in a meta-analysis by Zhan Huong et al. (2017), which suggested that the PAI-1 4G/5G polymorphism increases miscarriage susceptibility in various populations²⁷.

Conversely, studies from Poland (Kurzawińska et al., 2016) and Sudan found no significant association between PAI-1 polymorphisms and miscarriage, potentially due to geographical differences^{21, 28}.

The current study also found a significant association between miscarriage and parity (P-value ≤ 0.001), differing from Bigdeli et al. (2018), who found no significant relationship between gravidity, parity, and miscarriage²⁹. Regarding anthropometric characteristics, no link was found between BMI and supplement use and miscarriage, consistent with Bigdeli et al. (2018). However, a study in Karachi, Pakistan, found higher BMI associated with increased miscarriage risk³⁰. While smoking is a recognized risk factor for miscarriage, this study did not find a significant association, diverging from research in Sofia, Poland, and the Middle East, which consistently linked smoking to increased miscarriage risk^{31, 32, 33}.

REFERENCES

1. Seyed Alireza Dastgheib1, Mojgan Karimi-Zarchi2, et al., meta-analysis of the association of the ACE I/D and PAI-1 4G/5G polymorphisms with recurrent pregnancy loss in Iranian women. DOI:10.4274/tjod.galenos.2021.58997 Turk J Obstet Gynecol 2021;18:139-150A
2. Aslbahar F, Neamatzadeh H, Tabatabaiee R, Karimi-Zarchi M, Javaheri A, Mazaheri M, et al. Association of angiotensin-converting enzyme insertion/deletion polymorphism with recurrent pregnancy loss: a meta-analysis of 26 case-control studies. Rev Bras Ginecol Obstet 2018;40:631-41.
3. Maziri P, Tehrani GA, Hidagi FB, Nejatollahi M, Asadi S. Association between thrombophilic gene polymorphisms and recurrent pregnancy loss in Iranian women. Iranian Journal of Neonatology 2017;8:13-9.

4. Kamali M, Hantoushzadeh S, Borna S, Neamatzadeh H, Mazaheri M, Noori-Shadkam M, et al. Association between thrombophilic genes polymorphisms and recurrent pregnancy loss susceptibility in Iranian women: A systematic review and meta-analysis. *Iran Biomed J* 2018;22:78-89.
5. Behforouz A, Dastgheib SA, Abbasi H, Karimi-Zarchi M, Javaheri A, Hadadan A, et al. Association of MMP-2, MMP-3, and MMP-9 polymorphisms with susceptibility to recurrent pregnancy loss. *Fetal Pediatr Pathol* 2020:1-9.
6. Soleimani-Jadidi S, Abbasi H, Javaheri A, Behforouz A, Zambagh L, Meibodi B, et al. Cumulative evidence for association of il-10 -1082g > a polymorphism with susceptibility to recurrent pregnancy loss: a systematic review and meta-analysis. *Fetal Pediatr Pathol* 2020:1-15.
7. Heidari MM, Sheikholeslami M, Yavari M, et al. The association of renin–angiotensinogen system genes polymorphisms and idiopathic recurrent pregnancy loss. *Hum Fertil (Camb)* 2017;22:164-70.
8. Neamatzadeh H, Ramazani V, Kalantar SM, Ebrahimi M, Sheikhha MH. Serum immune reactivity against β 2-Glycoprotein-I and antineutrophil cytoplasmic auto-antibodies by ELI-P-Complex Screening Technology in RPL. *Minerva Ginecol* 2016;68:243-9.
9. Colucci G, Tsakiris DA. Thrombophilia screening revisited: an issue of personalized medicine. *J Thromb Thrombolysis* 2020;49:618-29.
10. Simcox LE, Ormesher L, Tower C, Greer IA. Thrombophilia and pregnancy complications. *Int J Mol Sci* 2015;16:28418-28. doi:10.3390/ijms161226104.
11. Ormesher L, Simcox L, Tower C, Greer IA. Management of inherited thrombophilia in pregnancy. *Womens Health (Lond)* 2016;12:433-41.
12. Nassour-Mokhtari I, Loukidi B, Moussouni A, Merzouk H, et al. Inherited thrombophilia and recurrent pregnancy loss: a single-center case-control study in North-Western Algeria. *Egyptian J Med Hum Genet* 2020;21:1-7.
13. El Hachem H, Crepaux V, May-Panloup P, et al. Recurrent pregnancy loss: current perspectives. *Int. J. wom. Heal.* 2017; 9:331. <https://doi.org/10.214 7/IJWH.S100817.1>.
14. Arias-Sosa LA, Acosta ID, Lucena-Quevedo E, et al. Genetic and epigenetic variations associated with idiopathic recurrent pregnancy loss. *J. Assist. Reprod. Genet.* 2018; 35: 355–366. <https://doi.org/10.1007/s10815-017-1108-y>.
15. Vomstein K, Feil K, Strobel L, et al. Immunological Risk Factors in Recurrent Pregnancy Loss: Guidelines Versus Current State of the Art. *Journal of Clinical Medicine.* 2021; 10(4): 869. <https://doi.org/10.3390/jcm10040869>
16. Ghaebi M, Nouri M, Ghasemzadeh A, et al. Immune regulatory network in successful pregnancy and reproductive failures. *Biomed. Pharmacother.* 2017; 88: 61–73. <https://doi.org/10.1016/j.biopha.2017.01.016>.
17. Babker AM, Gameel FE. Molecular Characterization of Prothrombin G20210A gene Mutations In pregnant Sudanese women with spontaneous recurrent abortions. *Rawal Medical Journal.* 2015 Apr 1;40(2):207-9.

18. Hyde KJ, Schust DJ. Genetic considerations in recurrent pregnancy loss. *Cold Spring Harb Perspect Med.* 2015 Feb 6;5(3):a023119. doi: 10.1101/cshperspect. a023119. PMID: 25659378; PMCID: PMC4355257.
19. Babker AM, Gameel FE. Methylenetetrahydrofolate reductase c677t polymorphism in Sudanese women with recurrent spontaneous abortions. *Kuwait Medical Journal.* 2016;48(2):100–104.
20. Gintoni I, Adamopoulou M, Yapijakis C. The Angiotensin converting Enzyme Insertion/Deletion Polymorphism as a Common Risk Factor for Major Pregnancy Complications. *In Vivo.* 2021 Jan-Feb;35(1):95-103. doi: 10.21873/ invivo.12236.
21. Hanan K. Ahmed1, Amanda G. Elgoraish1, et al. Association of Plasminogen Activator Inhibitor-1 4G/5G and Angiotensin-Converting Enzyme I/D Polymorphisms with Recurrent Pregnancy Loss in Sudanese Women: A Case-Control study *International Journal of Biomedicine* 13(1) (2023) 127-133 [http://dx.doi.org/10.21103/Article13\(1\)_OA18](http://dx.doi.org/10.21103/Article13(1)_OA18)
22. Zhang S, Wang J, Wang B, Ping Y, Ma X. Strong association between angiotensin I-converting enzyme I/D polymorphism and unexplained RPL of Chinese women--a case-control study. *Reprod Sci.* 2011 Aug;18(8):743-6. doi: 10.1177/1933719111415865.
23. Fazelnia S, Farazmandfar T, Hashemi-Soteh SM. Significant correlation of angiotensin converting enzyme and glycoprotein IIIa genes polymorphisms with unexplained recurrent pregnancy loss in north of Iran. *Int J Re prod Biomed (Yazd).* 2016; 14(5): 323–328, indexed in Pubmed: 27326417.
24. Patil, Rucha; Ghosh, Kanjaksha; Vora, Sonal; Shetty, Shrimati Source: Blood cells, molecules & diseases. *Gov't Journal Article,* 2015; 55 (3): 200-205. PubMedID: 26227844.
25. Al-Mukaynizi FB, AlKhuriji A, Babay Z, et al. Lack of Association between Angiotensin Converting Enzyme I/D Polymorphism and Unexplained RPL in Saudi Arabia. *J Med Biochem.* 2016; 35(2): 166–173, doi: 10.1515/jomb-2015-0020, indexed in Pubmed: 28356877.
26. Aarabi M, Memariani T, Arefi S, et al. Polymorphisms of plasminogen activator inhibitor-1, angiotensin converting enzyme and coagulation factor XIII genes in patients with recurrent spontaneous abortion. *J Matern Fetal Neonatal Med.* 2011 Mar;24(3):545-8. doi: 10.3109/14767058.2010.511331.
27. Zhan Huang 1, Wenqian Tang 2, Zhikun Liang 1, et al. An Updated Meta-Analysis Plasminogen Activator Inhibitor-1 Polymorphism Confers a Genetic Contribution to the Risk of Recurrent Spontaneous Abortion: An Updated Meta-Analysis. 2017; 24: 1551–1560. PMID: 28395596.
28. Kurzawińska G, Barlik M, Drews K, et al. Coexistence of ACE (I/D) and PAI-1 (4G/5G) gene variants in RPL in Polish population. 2016;87(4):271-6. doi: 10.17772/gp/62203.
29. Bigdeli R, Younesi MR, Panahnejad E, et al. Association between thrombophilia gene polymorphisms and recurrent pregnancy loss risk in the Iranian population. *Systems Biology in Reproductive Medicine.* 2018;1080.DOI:10.1080/19396368.2018.1456576
30. Zafar Iqbal , Syed Daniyal A., Lalitha P. et al. Evaluating the Clinical Risk Factors Associated With Miscarriages in Women in Karachi, Pakistan. 2021;13(10):e19057. DOI: 10.7759/cureus.1905
31. Ivanov P, Konova E, Komsa-Penkova R, et al. [Preplacental pregnancy loss in cases of angiotensin-converting enzyme insertion/deletion polymorphism]. *Akush Ginekol (Sofia).* 2014; 53(4): 12–16, indexed in Pubmed: 25510065.
32. Poloska A, Gjonej R: Evaluation of spontaneous and voluntary abortions in years in relation with abortions . *Int J Sci Res.* 2015;24:38-55.
33. Zargar M, Razmkhah N, Nikbakht R: Evaluating the factors associated with pregnancy loss in pregnant women undergoing assisted reproductive techniques. *Middle East Fertil Soc J.* 2018, 23:342-5. 10.1016/j.mefs.2018.04.009.